Document is current

Article History

Received: 1 July 2021

Revised: 13 December 2021

Accepted: 7 January 2022

First Online: 14 January 2022

Declarations

:

: This study was approved by the Department of Ethics Review Committee of Nagoya University Graduate School of Medicine (2018–0315).

: This study was conducted retrospectively from data obtained for clinical purposes, and the requirement for informed consent was waived.

: Not applicable.

: IO, SM, HF, and AN declare no competing interests. KI has received speakers’ honoraria from Eisai, Kyowa, Meiji Seika Pharma, Otsuka, Sumitomo Dainippon, Taisho, Takeda, and Towa. NO has received research support or speakers’ honoraria from, or has served as a consultant to, Sumitomo Dainippon, Eisai, Otsuka, KAITEKI, Mitsubishi Tanabe, Shionogi, Eli Lilly, Mochida, DAIICHI SANKYO, Nihon Medi-Physics, Takeda, Meiji Seika Pharma, EA Pharma, Pfizer, MSD, Lundbeck Japan, and Taisho Pharma, Janssen, UCB and Shionogi, Nihon Medi-Physics, Tsumura, Novartis, and Astellas.